A Phase 2, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety and Tolerability of Pradigastat in Patients With Functional Constipation

The purpose of this study is to evaluate the efficacy, safety, and tolerability of pradigastat 20 and 40 mg as compared to placebo in patients with Functional Constipation.

开始日期2020-09-22

申办/合作机构

Anji Pharmaceuticals, Inc.初创企业

[+1]

NL-OMON41457

/ Completed临床3期

An open label, long term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome - LCQ908 extension study

开始日期2013-10-31

申办/合作机构

Novartis AG

100 项与 Pradigastat 相关的临床结果

登录后查看更多信息

100 项与 Pradigastat 相关的转化医学

登录后查看更多信息

100 项与 Pradigastat 相关的专利（医药）

登录后查看更多信息

项与 Pradigastat 相关的文献（医药）

2021-03-01·European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2区 · 医学

A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism

2区 · 医学

Article

作者: Liu, Jia ; Dang, Xiang-Yu ; Lin, Fei-Fei ; Yang, Yang ; Wang, Ting ; Hu, You-Hong ; Huang, Jun-Shang ; Guo, Bin-Bin ; Wang, He-Yao ; Zeng, Li-Min

Diacylglycerol acyltransferase 1 (DGAT1) plays a pivotal role in lipid metabolism by catalyzing the committed step in triglyceride (TG) synthesis and has been considered as a potential therapeutic target of multiple metabolic diseases, including dyslipidemia, obesity and type 2 diabetes. Here we report a novel DGAT1 inhibitor, Yhhu2407, which showed a stronger DGAT1 inhibitory activity (IC₅₀ = 18.24 ± 4.72 nM) than LCQ908 (IC₅₀ = 78.24 ± 8.16 nM) in an enzymatic assay and led to a significant reduction in plasma TG after an acute lipid challenge in mice. Pharmacokinetic studies illustrated that Yhhu2407 displayed a low systemic, liver- and intestine-targeted distribution pattern, which is consistent with the preferential tissue expression pattern of DGAT1 and therefore might help to maximize the beneficial pharmacological effects and prevent the occurrence of side effects. Cell-based investigations demonstrated that Yhhu2407 inhibited free fatty acid (FFA)-induced TG accumulation and apolipoprotein B (ApoB)-100 secretion in HepG2 cells. In vivo study also disclosed that Yhhu2407 exerted a beneficial effect on regulating plasma TG and lipoprotein levels in rats, and effectively ameliorated high-fat diet (HFD)-induced dyslipidemia in hamsters. In conclusion, we identified Yhhu2407 as a novel DGAT1 inhibitor with potent efficacy on improving lipid metabolism in rats and HFD-fed hamsters without causing obvious adverse effects.

2021-02-01·Acta pharmacologica Sinica1区 · 医学

DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis

1区 · 医学

Article

作者: Wang, Gai-Hong ; Hu, You-Hong ; Wang, He-Yao ; Wang, Ting ; Huang, Jun-Shang ; Guo, Bin-Bin ; Zeng, Li-Min

Previous studies demonstrated that prolonged exposure to elevated levels of free fatty acids (FFA), especially saturated fatty acids, could lead to pancreatic β-cell apoptosis, which plays an important role in the progression of type 2 diabetes (T2D). Diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step of triglyceride (TG) synthesis, has been reported as a novel target for the treatment of multiple metabolic diseases. In this study we evaluated the potential beneficial effects of DGAT1 inhibitors on pancreatic β-cells, and further verified their antidiabetic effects in db/db mice. We showed that DGAT1 inhibitors (4a and LCQ908) at the concentration of 1 μM significantly ameliorated palmitic acid (PA)-induced apoptosis in MIN6 pancreatic β-cells and primary cultured mouse islets; oral administration of a DGAT1 inhibitor (4a) (100 mg/kg) for 4 weeks significantly reduced the apoptosis of pancreatic islets in db/db mice. Meanwhile, 4a administration significantly decreased fasting blood glucose and TG levels, and improved glucose tolerance and insulin tolerance in db/db mice. Furthermore, we revealed that pretreatment with 4a (1 μM) significantly alleviated PA-induced intracellular lipid accumulation, endoplasmic reticulum (ER) stress, and proinflammatory responses in MIN6 cells, which might contribute to the protective effects of DGAT1 inhibitors on pancreatic β-cells. These findings provided a better understanding of the antidiabetic effects of DGAT1 inhibitors.

2020-06-01·Digestive diseases and sciences3区 · 医学

Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center

3区 · 医学

Article

作者: Hardiman, Karin M ; Berinstein, Jeffrey A ; Govani, Shail M ; Waljee, Akbar K ; Stidham, Ryan W ; Higgins, Peter D R

BACKGROUND:

Infliximab can prevent colectomy in patients hospitalized with acute severe ulcerative colitis (ASUC). In cases of ASUC, fecal losses of infliximab may lead to low drug levels and reduced efficacy.

AIM:

To determine 90-day colectomy risk and postoperative complications in patients receiving single-dose and accelerated induction of infliximab for ASUC.

METHODS:

We conducted a retrospective review of patients hospitalized with ASUC requiring infliximab therapy between 2013 and 2017 at the University of Michigan. Patients were excluded if they had an enteric infection, received an anti-TNF previously, or received cyclosporine during the same admission. The primary outcome was colectomy within 90 days of admission. Patients receiving single-dose induction infliximab were compared to those receiving accelerated rescue induction with two doses of infliximab prior to day 14. Administration of accelerated induction was guided by a protocol, suggesting administering a second dose of infliximab to those with only a partial response in CRP 3 days after the initial dose. Postoperative outcomes including 30-day readmission rates and complications were compared using descriptive statistics.

RESULTS:

From 2013 to 2017, 66 patients with ASUC met our criteria. Thirty-three received accelerated induction (50.0%). The colectomy rate in the accelerated induction group was 30.3% versus 24.2% in the single-dose induction group (p = 0.58). There was no detected difference in postoperative outcomes between the accelerated and single-dose rescue induction.

CONCLUSIONS:

In this retrospective review, 69.7% of those failing to respond to single-dose infliximab were able to avoid colectomy with an accelerated rescue induction strategy without worsening postoperative outcomes. Larger studies of accelerated dosing infliximab are needed.

项与 Pradigastat 相关的新闻（医药）

2024-12-15

·药事纵横

华人科学家再联合创业，融了2.15亿美金B轮的Biotech

▲3月6-7日上海长三角新药创新者峰会扫码免费报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。药融圈获悉：减肥领域新药公司Metsera由Population Health Partners和ARCH Venture Partners创立于2022年，总部在美国纽约。2024年4月份，完成的2.9亿美元融资。连续融资：上个月，2024年11月13日，Metsera完成2.15亿美元新一轮B轮融资。本轮融资由Wellington Management和Venrock Healthcare Capital Partners领投；Fidelity、Janus Henderson Investors、T.Rowe Price Associates和T.Rowe Price Investment Management、Viking Global Investors、Deep Track Capital、RA Capital Management新投资者参与了本轮融资。现有Metsera的投资者包括ARCH Venture Partners、Alpha Wave Ventures、GV、SoftBank Vision Fund 2、Newpath Partners、SymBiosis等同样参与本轮。公司的CSO 和转化医学负责人等则是创业老兵，此前在安济药业：安济药业（Anji Pharma）是一家新兴的全球医药公司，由时任首席执行官Brian Hubbard博士创立。他曾在博德研究所、默克、诺华和千年制药等公司领导药物研发。安济药业的联合创始人还包括：首席医学官Dan Meyers博士，曾设计和领导了40多个临床试验；华人首席科学官Mike Serrano-Wu博士，参与研发了daclatasvir、pradigastat和其他5个已进入临床试验阶段的候选药物分子。2022年10月19日，安济药业和Population Health Partners正式宣布达成战略合作。 ▲ Metsera CEO Clive Meanwell Metsera的核心产品MET-097正在进行1/2期试验，本品是一种新型的、偏向的、每月一次注射的GLP-1 候选分子；MET-233i是一种超长效胰淀素类似物（amylin）；其他还有口服GLP-1 肽类MET-002；MET-034i，一种超长效HALO™脂化GIP RA新药；还包括胰岛淀粉样肽/降钙素双重受体激动剂（DACRA），单分子GGG等等。公司拥有一整套营养刺激激素（NuSH）类似肽库用于候选药物开发。 ▲https://pharma.bcpmdata.com/database/24/detail/441/mb94LZMBlWZ1TLUOcEWj 2024年9月，MET-097的一期临床数据披露：MET-097实现380小时的半衰期，将可用于每月给药方案；1.2mg剂量组下，患者治疗5周后（36天）减重7.5%；最后一次停药后4周减重幅度扩大至8.1%，提示药效保持时间与潜在的超长半衰期相符合。体重管理，合理健康减重 2024年10月，Metsera宣布与 Amneal Pharmaceuticals 建立供应链领域合作关系；据悉这家美国上市公司 Amneal 将成为 Metsera 在包括美国和欧洲在内的发达市场的“首选供应合作伙伴”。Amneal 还将拥有在一些新兴市场商业化 Metsera 产品的权益许可。参考： NMPA/CDE 药融云数据，www.pharnexcloud.com；改名后为摩熵医药数据； FDA/EMA/PMDA；相关公司公开披露； https://www.businesswire.com/news/home/20240924023447/en/Metsera-Reports-Highly-Competitive-Results-from-Ongoing-Trial-of-Novel-Potential-Once-Monthly-Injectable-GLP-1-Receptor-Agonist-MET-097； https://metsera.com； https://endpts.com/the-endpoints-11-2024-winners-big-bets-on-ai-new-frontiers-in-editing-a-neuro-renaissance-and-chinese-chemistry/； https://amneal.com/；等等。本文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场，不作任何用药推荐。

临床1期

2024-11-18

·生物制药小编

新晋减肥Biotech：CSO此前是国内企业创始人

尽管近年来GLP-1减肥药赛道拥挤不断，但是仍然有企业能够脱颖而出，融到资金。近日，新晋减肥药公司Metsera宣布了2.15亿的B轮融资，这距离该公司今年4月份2.9亿美元的A轮融资仅仅过去7个月，Metsera显然有从竞争环境中脱颖而出的潜力。卖点：轻微副作用，不涉及剂量渐增，每月一次从该公司9月发布的I期临床信息来看，Metsera目前进度最快的管线是长效可注射GLP-1受体激动剂MET-097，该管线采用Metsera的HALO脂质平台设计。注射间隔为每个月一次，接受MET-097i治疗的参与者在第36天的体重比基线下降了7.5%。比较值得称道的是该药物的安全性效果。一般而言，已批准的减肥药需要通过滴定的缓慢增加剂量来适应剂量的时期，不然就可能出现胃肠道相关副作用。比如说，例如，司美格鲁肽一般被建议从0.25mg小剂量起始，单次注射逐步增加到1mg。而相比于目前市面上的司美格鲁肽和替尔泊肽，MET-097的临床不需要涉及剂量渐增，而且副作用看上去非常轻微。这一方面简化了患者的给药模式，另外一方面还优化了安全性问题。另外，该公司还有该公司有一个完整的营养刺激激素(NuSH)模拟肽库，该肽库建立在大约2万种NuSH模拟肽的基础上，并通过二十年的经验生物学研究和先进的肽工程开发而成，可从中推出多种药物候选物，目前该公司还有MET-034i，MET-233i等管线。目前推测，技术来源于收购GLP-1研究的领军人物Stephen Bloom的小微公司Zihipp和韩国公司D&D Pharmatech。在这种情况下，吸引多位高端投资者的两轮次融资似乎再正常不过，值得一提的是，如果查看Metsera的技术团队，会惊讶地发现CSO是以前一家中国药企的联合创始人之一。 CSO此前是国内企业创始人如果仔细看Metsera的技术掌舵团队，会发现此前与中国Biotech安济药业（Anji Pharma）的一致之处都是CSO Brian Hubbard，研发负责人（转化医学）的Mike Serrano-Wu。这两位显然都是新药猎人“老兵”。安济药业此前是由CRO公司维亚生物所孵化的，董事长也是维亚生物的创始人毛晨博士。CEO是现在博致生物首席运营官宗宜伟博士。当时具有的管线是收购自Elcelyx Therapeutics的ANJ900（二甲双胍延迟释放新剂型）和授权自诺华的DGAT1抑制剂ANJ908（pradigastat），授权自LipimetiX Development（Capstone Therapeutics子公司）的多肽创新药AEM-28。适应症方面，ANJ900旨在针对那些有着慢性肾病的二型糖尿病患者，ANJ908主要用于便秘，AEM-28用于严重的孤儿高胆固醇血症。值得一提的是，维亚生物孵化的另外一家企业 Dogma Therapeutics的技术骨干也是Brian Hubbard和Mike Serrano-Wu，Dogma开发的主要是PCSK9小分子药物，目前已经授权给了阿斯利康，研发代码为AZD0780。总结总的来说，Metsera的崛起速度非常之快，收购管线抓住了现有药物的弊端，做出了差异化，技术团队选取了新药猎人“老兵”掌舵，可以期待未来该公司的更多信息。参考来源： https://metsera.com/news https://www.sohu.com/a/594125812_120455786 https://www.dogmatherapeutics.com/

并购临床1期

2023-05-16

·BioSpace

Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810

- TTX-810 is designed for rapid clearance to circumvent mechanism-based risks of MCL1 inhibition - High potency affords robust anti-tumor effects whilst preserving cardiomyocyte viability - Trueline Therapeutics on track to initiate clinical development of TTX-810 CAMBRIDGE, Mass., & BERLIN--(BUSINESS WIRE)-- Trueline Therapeutics Inc., an oncology-focused subsidiary of Anji Pharmaceuticals, today announced the successful completion of IND-enabling studies with MCL1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers. A distinguishing feature of TTX-810 is a rapid clearance pro minimize the potential risks of sustained MCL1 inhibition in non-cancerous tissues. “The completion of IND-enabling studies marks the culmination of over a decade’s work to truly understand the safest and most effective way to approach MCL1 inhibition,” said Ulla Rauh, Ph.D., CEO/CSO of Trueline Therapeutics. “With our rapid-clearance strategy further de-risked, we are excited to progress TTX-810 into cancer patients and finally unlock the therapeutic potential of MCL1 inhibition.” TTX-810 was discovered by a partnership between the Broad Institute of Harvard and MIT and Bayer Pharmaceuticals. The exquisite potency of TTX-810 was achieved by structure-guided design and comprehensive profiling versus over 500 cancer cell lines to define the optimal cellular context for rapid and selective induction of cell death. Following candidate selection, Trueline Therapeutics scientists designed and executed the IND-enabling program in preparation for first-in-human testing. “When we first saw the TTX-810 data package, our key questions were ‘Will it work?’ and ‘Will it be safe?’ given the challenges other therapeutic candidates with more traditional clearance profiles are encountering,” said Michael Serrano-Wu, Ph.D., Chief Scientific Officer of Anji Pharmaceuticals. “This approach benefits from the rapid and irreversible effects of MCL1 inhibition, which we believe offers a therapeutic window not attainable with longer-acting compounds. We customized our IND-enabling program to address these questions, and now it is full steam ahead to demonstrate the clinical advantages of this unique profile.” About Trueline Therapeutics Inc. Trueline Therapeutics is an oncology-focused subsidiary of Anji Pharmaceuticals. In addition to the MCL1 inhibitor TTX-810, TruelineTx is developing a CD3/CD33 bi-specific called TTX-564 which has been shown to be safe in cancer patients and induce strong depletion of immunosuppressive cells called myeloid-derived suppressor cells (MDSCs). A dual HCK/BTK inhibitor, TTX-114 is in preclinical development. For more information visit . About Anji Pharmaceuticals Inc. Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients across the globe. Anji’s asset-centric business model allows for speed and flexibility in building value, leveraging a clinical and regulatory core that operates with “hub-and-spoke” efficiency. Since its founding in 2018, Anji Pharma has launched clinical trials for two late-stage development programs: ANJ900 for glucose management in T2D and CKD and ANJ908 as a new mechanism for chronic constipation. For more information, visit .

临床申请临床研究

100 项与 Pradigastat 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10664	-	-	DB12866

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性乳糜微粒血症综合征	临床3期	美国	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	法国	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	德国	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	荷兰	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	南非	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	西班牙	Novartis Pharmaceuticals Corp.	2012-07-01
家族性乳糜微粒血症综合征	临床3期	英国	Novartis Pharmaceuticals Corp.	2012-07-01
功能性便秘	临床2期	美国	Anji Pharmaceuticals, Inc.初创企业	2020-09-22
功能性便秘	临床2期	中国	Anji Pharmaceuticals, Inc.初创企业	2020-09-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01387958 (Pubmed \| ACS Infect Dis) 人工标引	N/A	丙型肝炎	32	Pradigastat	鏇鑰簾窪繭積積鹹衊餘(醖積觸鑰淵壓蓋衊積範) = Most treatment-emergent adverse events were gastrointestinal; there were no hepatic adverse events. 鏇顧鑰憲製艱餘顧襯窪 (顧網網窪鬱簾獵獵願憲 )	不佳	2017-02-10
				Placebo
NCT01811472 (CTgov)	临床2期	代谢功能障碍相关的脂肪肝病	52	placebo (Placebo)	鏇憲襯繭艱顧選襯壓壓(憲鏇壓衊鏇壓鬱築網醖) = 構選鏇遞鑰簾夢繭膚製醖網築襯簾窪築遞餘遞 (製艱遞糧壓顧糧觸鹹鏇, 衊蓋繭壓選鹽夢觸觸廠 ~ 襯鬱窪觸構構簾鏇積廠) 更多	-	2016-02-04
				LCQ908 (Pradigastat (LCQ908) 5mg/10mg)	鏇憲襯繭艱顧選襯壓壓(憲鏇壓衊鏇壓鬱築網醖) = 鬱糧醖遞夢範膚壓觸範醖網築襯簾窪築遞餘遞 (製艱遞糧壓顧糧觸鹹鏇, 簾鹽範繭壓獵憲廠選鬱 ~ 獵蓋壓築選範繭築淵廠) 更多
NCT01594957 (Pubmed \| Clin Pharmacokinet) 人工标引	临床1期	肝损伤	16	Pradigastat	製範鑰願築鏇選範襯築(遞鹹願壓鹹製蓋餘壓窪) = 遞醖構廠鏇願獵窪鏇選鏇壓顧憲襯艱鬱製範選 (選鑰鬱製齋鏇鏇繭醖範 )	积极	2015-07-01
NCT01514461 (CTgov)	临床3期	家族性乳糜微粒血症综合征	45	Placebo (Placebo)	衊遞鑰蓋齋窪蓋窪簾範(積鑰壓網範鏇夢顧齋衊) = 簾衊範簾範鏇製衊顧簾選膚壓選願蓋鹽廠齋蓋 (鹹鏇窪構範壓選蓋選顧, 壓範糧構範積齋窪範獵 ~ 鑰襯鹹製鹽壓淵觸衊顧) 更多	-	2015-06-03
				Placebo+LCQ908 (LCQ908 40 mg)	衊遞鑰蓋齋窪蓋窪簾範(積鑰壓網範鏇夢顧齋衊) = 鹽襯鹹餘觸襯構膚壓觸選膚壓選願蓋鹽廠齋蓋 (鹹鏇窪構範壓選蓋選顧, 網醖憲遞襯築醖遞餘構 ~ 廠廠艱積糧獵獵艱積觸) 更多